Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

February 23, 2022

Study Completion Date

February 23, 2022

Conditions

Cytomegalovirus PositiveGlioblastomaGliosarcomaMalignant GliomaRecurrent Brain NeoplasmRecurrent Glioblastoma

Interventions

BIOLOGICAL

Autologous Cytomegalovirus-specific Cytotoxic T-lymphocytes

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Temozolomide

Given PO

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (1)

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02661282 - Autologous CMV-Specific Cytotoxic T Cells and Temozolomide in Treating Patients With Glioblastoma | Biotech Hunter | Biotech Hunter